Theodore Osuala, MD
Psychiatry · Lanham, MDNPI 1356428833
Payments from drug & device makers
Across 276 payments — averaging $22.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$1K
- AbbVie$890
- Vanda Pharmaceuticals Inc.$844
- Otsuka America Pharmaceutical, Inc.$774
- Teva Pharmaceuticals USA, Inc.$532
- Lundbeck LLC$520
- plus $2K from 17 others
What the payments were for
- Food & beverage$6,17798%
- Education$1502%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 37 | $1,135 |
| AbbVie(2 entities) | 50 | $890 |
| Vanda Pharmaceuticals Inc. | 39 | $844 |
| Otsuka America Pharmaceutical, Inc. | 29 | $774 |
| Teva Pharmaceuticals USA, Inc. | 22 | $532 |
| Lundbeck LLC | 26 | $520 |
| Johnson & Johnson | 14 | $386 |
| Neurocrine Biosciences, Inc. | 8 | $303 |
| E.r. Squibb & Sons, L.L.C. | 12 | $205 |
| Alkermes, Inc. | 11 | $189 |
| Sunovion Pharmaceuticals Inc. | 4 | $102 |
| Supernus Pharmaceuticals, Inc. | 5 | $86 |
| Indivior Inc. | 3 | $77 |
| Axsome Therapeutics, Inc. | 3 | $70 |
| Corium, LLC | 3 | $42 |
| Noven Therapeutics, LLC | 2 | $33 |
| Eisai Inc. | 2 | $33 |
| Tris Pharma Inc | 1 | $21 |
| Almatica Pharma LLC | 1 | $21 |
| Ironshore Pharmaceuticals Inc. | 1 | $19 |
| Janssen Scientific Affairs, LLC | 1 | $17 |
| Orexo US, Inc. | 1 | $14 |
| Jazz Pharmaceuticals Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- CAPLYTA$287
- ABILIFY MAINTENA$234
- ABILIFY ASIMTUFII$234
- INGREZZA$140
- VRAYLAR$106
How this compares
$6,327 in reported general payments places this provider in the 90th percentile of 851 psychiatry providers in Maryland.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Invega SustennaPaliperidone Palmitate | 64 | $193,840 |
| IngrezzaValbenazine Tosylate | 21 | $184,745 |
| Abilify MaintenaAripiprazole | 26 | $64,303 |
| VraylarCariprazine Hcl | 30 | $57,266 |
| PerserisRisperidone | 14 | $37,112 |
| AristadaAripiprazole Lauroxil | 12 | $36,475 |
| RexultiBrexpiprazole | 14 | $23,116 |
| Risperdal ConstaRisperidone Microspheres | 14 | $17,302 |
| LoxapineLoxapine Succinate | 240 | $16,601 |
| Varenicline Tartrate | 50 | $15,402 |
| LinzessLinaclotide | 17 | $12,955 |
| NamzaricMemantine Hcl/Donepezil Hcl | 13 | $11,695 |
| Divalproex Sodium | 330 | $10,154 |
| ZubsolvBuprenorphine Hcl/Naloxone Hcl | 11 | $9,162 |
| Quetiapine Fumarate | 351 | $7,994 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonInvega Sustenna, Risperdal Consta | $386 | $211,14378 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $303 | $184,74521 claims |
| Otsuka America Pharmaceutical, Inc.Abilify Maintena, Rexulti | $774 | $87,41940 claims |
| AbbVieVraylar, Linzess, Namzaric | $890 | $81,91660 claims |
| Indivior Inc.Perseris | $77 | $37,11214 claims |
| Alkermes, Inc.Aristada | $189 | $36,47512 claims |
| Teva Pharmaceuticals USA, Inc.Loxapine | $532 | $16,601240 claims |
| Orexo US, Inc.Zubsolv | $14 | $9,16211 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 851 psychiatry providers in Maryland.
Other psychiatry in Lanham
- Elia Acevedo DiazGaithersburg$15.8M
- Akira SawaBaltimore$5.1M
- John VaethBaltimore$2.1M
- Paul RosenbergBaltimore$1.9M
- Scott AaronsonBaltimore$1.3M
- Karen AndersonBaltimore$1.1M
- Constantine LyketsosBaltimore$1.1M
- Alan JonasBaltimore$1.1M
- Sarah HertsBaltimore$1M
- Robert LehmanBaltimore$947K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.